Session Title: Quick Fire Free Paper Session 01
Session Date/Time: Thursday 26/09/2013 | 08:30-10:30
Paper Time: 08:30
Venue: Hall G1 (Level 2)
First Author: M.Zengin TURKEY
Co Author(s): C. Kucukerdonmez S. Sizmaz A. Kal G. Yilmaz
To evaluate and compare the effects of single intravitreal injection of ranibizumab and bevacizumab on central retinal and choroidal thickness in patients with neovascular age-related macular degeneration (AMD)
Prospective, randomized, interventional study
Forty eyes of 40 patients with neovascular AMD that underwent intravitreal injection of vascular endothelial growth factor inhibitors (anti-VEGFs) were included. Patients were randomized into two groups: Twenty eyes received ranibizumab and 20 eyes received bevacizumab injection. Central retinal and choroidal thicknesses of all eyes at baseline and 1 month post-injection scans were measured with Fourier-domain optical coherence tomography (OCT). Choroidal thickness measurements were taken at 7 points, with the fovea at the center. Student t test and Mann Whitney U test were used to compare the data.
The mean central retinal thickness (CRT) showed significant decrease after single injection of ranibizumab (from 345.0 microns to 253.5 microns, p<0.01) and bevacizumab (from 329.5 microns to 251.0 microns, p<0.01) at the first month, respectively. There was no significant difference regarding the CRT change between groups (p=0.39). The mean choroidal thickness decreased from 158.6 microns (115 – 317) to 155.5 microns (111 – 322) in ranibizumab group and from 211.5 microns (143 – 284) to 201.5 microns (93 – 338) in bevacizumab group. The decrease was not significant between groups (p=0.35).
Intravitreal injection of both ranibizumab and bevacizumab provided a significant decrease in central retinal thickness, however, both agents caused no significant change in choroidal thickness. Further studies are required to confirm the effect of anti-VEGF agents on choroid, which is assumed to play a role in the pathogenesis of AMD.